50 pitches found in hedge fund reports this week

Jul 9, 2026 · 09:23

↗ https://hfbestideas.substack.com/p/50-pitches-found-in-hedge-fund-reports

<div class="subscription-widget-wrap-editor"><div class="subscription-widget show-subscribe"><div class="preamble">Thanks for reading Stock Analysis Compilation! Subscribe for free to receive new posts and support my work.</div><form class="subscription-widget-subscribe"><input class="email-input" name="email" tabindex="-1" type="email" /><input class="button primary" type="submit" value="Subscribe" /><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><div><hr /></div><h3>Upgrade Your Edge on HFBestIdeas.com 🚀</h3>Stop spending hours sourcing and digesting Hedge Fund letters. Let HFBestIdeas do the manual work for you and turn over more rocks in less time. Try any premium plan free for 7 days:<ul><li>The Analyst ($10/mo): Full newsletter (35+ stock pitches/week).</li><li>The Associate ($19/mo): Full access to our pitch database + Quarterly Letter archive.</li><li>The Rainmaker ($29/mo): Total access + Warren AI, your proprietary research assistant.</li></ul>Note: For Associate & Rainmaker access, please subscribe directly at <a href="https://HFBestIdeas.com">HFBestIdeas.com</a>.<a class="button primary" href="https://www.hfbestideas.com/pricing">Start Your 7-Day Free Trial</a>Now, let’s get into this week’s selection of fund ideas 👇<div><hr /></div><h3>Summary :</h3>🔹 AIA Group (1299 HK) by Polen International Growth🔹 American Express (AXP US) by Giverny Capital🔹 ASML (ASML NA) by Polen Global Growth🔹 Bajaj Finance Limited (BAF IN) by Baron India Fund🔹 Banco Bradesco S.A. (BBDC4 BZ) by Baron Emerging Markets Fund🔹 Burford Capital (BUR FP) by Focus Capital Management🔹 CoStar Group, Inc. (CSGP US) by Baron Partners Fund🔹 Danaher (DHR US) by Eagle Capital Management🔹 Dassault Systèmes (DSY FP) by Harding Loevner International Equity🔹 Ducommun (DCO US) by Diamond Hill Small Cap Fund🔹 FIGS, Inc. (FIGS US) by Baron First Principles ETF🔹 Fortinet (FTNT US) by Emerald Growth Equity Strategy🔹 Freshpet Inc (FRPT US) by Artisan U.S. Small-Cap Growth Strategy🔹 Graham Corp. (GHM US) by Conestoga Capital Advisors🔹 Guidewire Software, Inc. (GWRE US) by Baron Focused Growth Fund🔹 Heartflow, Inc. (HTFL US) by Baron Discovery Fund🔹 HPSP Co., Ltd. (403870 KS) by Baron International Growth Fund🔹 Impinj (PI US) by WS Amati Global Innovation Fund🔹 Johnson & Johnson (JNJ US) by Baron Health Care Fund🔹 JSW Energy Limited (JSW IN) by Baron India Fund🔹 Lam Research (LRCX US) by Polen Focus Growth🔹 Lam Research Corporation (LRCX US) by Baron Durable Advantage Fund🔹 Legence Corp. (LGN US) by Conestoga Capital Advisors🔹 MercadoLibre (MELI US) by Harding Loevner Emerging Markets Equity🔹 Merck & Co., Inc. (MRK US) by Baron Health Care Fund🔹 Meta Platforms (META US) by Polen Global Growth🔹 MGM Resorts (MGM US) by Diamond Hill Mid Cap Fund🔹 MSCI Inc. (MSCI US) by Baron Durable Advantage Fund🔹 NVIDIA Corporation (NVDA US) by Baron Opportunity Fund🔹 Precision Wires India Limited (PWI IN) by Baron India Fund🔹 Public Storage (PSA US) by Baron Real Estate Fund🔹 Quanta Services, Inc. (PWR US) by Baron Durable Advantage Fund🔹 Recruit (6098 JP) by Harding Loevner International Equity🔹 Regal Rexnord (RRX US) by Diamond Hill Mid Cap Fund🔹 Rollins (ROL US) by Polen Focus Growth🔹 SAP (SAP GY) by Emerald Growth Equity Strategy🔹 SAP (SAP FP) by Eagle Capital Management🔹 Schneider Electric (SU FP) by Harding Loevner Global Equity🔹 ServiceNow (NOW US) by Polen Focus Growth🔹 Siemens Energy (ENR GY) by Polen International Growth🔹 Taiwan Semiconductor Manufacturing Company Limited (TSM US) by Baron Technology ETF🔹 Temenos Group (TEMN SW) by Harding Loevner International Small Companies Equity🔹 Tencent (700 HK) by Emerald Focused Equity Strategy🔹 Tristel plc (TSTL LN) by Artemis UK Smaller Companies Fund🔹 UL Solutions, Inc. (ULS US) by Conestoga Capital Advisors🔹 UnitedHealth Group (UNH US) by Eagle Capital Management🔹 Vista Energy, S.A.B. de C.V. (VIST US) by Baron Emerging Markets Fund🔹 Vulcan Materials Company (VMC US) by Baron Asset Fund🔹 Weyerhaeuser Co (WY US) by The Davenport Funds🔹 Eagle Capital Management (WDAY US) by Workday<div><hr /></div><h3>AIA Group $1299 HK by Polen International Growth</h3>Thesis: AIA Group is a leading Asian insurer with a strong agent network and structural growth tailwinds.Source: https://drive.google.com/file/d/1ne1KOJ9CJvWd9iM40krXdfrbojDwQ4Mj/view?usp=drivesdkAnalysis: Another new addition was Hong Kong-based AIA Group, one of the largest life and health insurance groups in Asia. A key competitive advantage is its large tied-agent network, where AIA is widely recognized for the quality and productivity of its agents. We believe AIA is well positioned to benefit from several potential structural tailwinds, including a growing middle class, aging populations, low insurance penetration, and rising health awareness. Looking ahead, we expect high single-digit premium growth and double-digit earnings growth over the next five years.<a href="https://www.hfbestideas.com/?q=1299+HK&page=1">Access our full research database on AIA Group</a><div><hr /></div><h3>American Express $AXP US by Giverny Capital</h3>Thesis: American Express is a premium payments and card franchise with strong brand power, rising spend, and attractive earnings growth at a fair valuation.Source: https://drive.google.com/file/d/1oA-DE0l0B4rsyqrtk6UrhUtpPJpdjZFG/view?usp=drivesdkAnalysis: We used most of our Ametek proceeds to establish a new position in American Express in March, at a price of $294. Probably many of you hold at least one American Express card. It’s one of the premier status brands in the world, with a customer base of prime borrowers who often pay hundreds of dollars a year for the privilege of earning lucrative rewards. Those same cardholders generally do not revolve loan balances, meaning Amex earns much more money from transaction fees and annual cardholder dues than it does in interest on monthly balances. It makes money because people transact with the card to earn rewards, not because they need to borrow money to make ends meet. Maybe. A simpler question would be: do cardholders like the product and want to use it? The answer there is a clear yes. Spending on the card has been rising faster than overall consumer spending in recent years and lately has been accelerating. Paraphrasing an American Express executive at a recent investor meeting, “We keep raising the card fee to match the value, and the demand keeps rising.” Cardholders seem keenly aware of the value they’re getting back on their spending. Similarly, merchants very much want the patronage of American Express’ wealthy cardholders, to the point that they fund a sizable portion of the rewards programs. This creates a virtuous cycle of American Express driving high spenders to participating merchants, who rebate a portion of their spending through rewards. Restaurants and shops want the customers, the customers want the rewards, and Amex plays matchmaker. We bought our shares after a recent 25% drop in the stock price amid outstanding earnings performance and conservative accounting for potential future credit losses. Amex continues to add premium cardholders at remarkable rates: it added 5.8 million new consumer card accounts in 2025 at an average annual fee above $210. Further, it is growing disproportionately among Gen-Z and Millennials: the company says premium cardholder growth with younger adults is 15% in the US and 20% internationally. Our purchase price represents a PE multiple of about 15 times the 2027 earnings estimate of ~$20 per share, a fair price for a business growing earnings 11%-13% per year and generating a return on equity above 30%.<a href="https://www.hfbestideas.com/?q=AXP+US&page=1">Access our full research database on American Express</a><div><hr /></div><h3>ASML $ASML NA by Polen Global Growth</h3>Thesis: ASML is a monopolistic lithography equipment leader with major barriers to entry, semiconductor tailwinds, and high-teens earnings growth potential.Source: https://drive.google.com/file/d/1VU_RjjWsQMmlxSGcyCXrY9dKHPPbdyMC/view?usp=drivesdkAnalysis: Finally, we initiated a small position in ASML, the leading global provider of lithography machines to the semiconductor industry and the only global provider of extreme ultraviolet lithography (EUV) equipment necessary for advanced semiconductor manufacturing. ASML’s machines print minute detail onto silicon wafers. This minute detail is what drives improvement in chip performance, powering technological progress. ASML commands a monopolistic position within its segment of the semi supply chain (in some sub-segments it has 100% market share) and the technological complexity of its equipment creates an enormous barrier to entry. ASML should benefit from the strong semi cycle—both for memory and logic—that we think is likely to persist until the end of the decade. Additionally, recent innovation in light source technology could improve ASML’s machine throughput which would potentially translate into much higher pricing for their machines in the future. Given the various industry tailwinds, we expect ASML should be able to grow earnings at a high-teens rate or better.<a href="https://www.hfbestideas.com/?q=ASML+NA&page=1">Access our full research database on ASML</a><div><hr /></div><h3>Bajaj Finance Limited $BAF IN by Baron India Fund</h3>Thesis: Bajaj Finance Limited is a top NBFC with strong management and conservative risk controls positioned to benefit from secular growth in Indian consumer finance.Source: https://drive.google.com/file/d/1I7yFweUy18m_5SjAOfVEKe-JPlD_E1kl/view?usp=drivesdkAnalysis: Bajaj Finance Limited is a leading non-bank financial company in India. Shares declined during the quarter as geopolitical tensions over the past month raised expectations of higher inflation and disrupted India’s easing interest rate environment, which could negatively impact consumption-led credit growth. We retain conviction in the company due to its best-in-class management team, robust long-term growth outlook, and conservative risk management frameworks. We believe Bajaj is well positioned to benefit from growing demand for consumer financial services in India, including mortgages, personal loans, consumer durable loans, and other related products.<a href="https://www.hfbestideas.com/?q=BAF+IN&page=1">Access our full research database on Bajaj Finance Limited.</a><div><hr /></div><h3>Banco Bradesco S.A. $BBDC4 BZ by Baron Emerging Markets Fund</h3>Thesis: Banco Bradesco S.A. is a major Brazilian bank undergoing a profitability turnaround toward high-teens ROE driven by mix shift, cost initiatives, and digital adoption.Source: https://drive.google.com/file/d/1kz7aqHcW-zuGgXCZ968Ew0d9bbnCO1hv/view?usp=drivesdkAnalysis: During the quarter, we also initiated a position in Banco Bradesco S.A., one of Brazil’s largest private-sector banks, serving customers through a diversified offering that includes lending, insurance, pensions, and asset management, among others. We believe Bradesco is in the early stages of a multi-year recovery in profitability, with ROE expected to expand from the mid-teens toward the high teens as the bank executes its transformation plan. The turnaround is being driven by the company’s shift in the loan mix toward higher-quality, collateralized products, which is enhancing risk-adjusted returns. We also see meaningful upside from cost initiatives that have yet to be fully reflected, including branch rationalization and increased digital adoption, which should drive operating leverage and efficiency gains over time. Additional support comes from continued growth in higher-return lending segments, lower funding costs and capital benefits from the use of deferred tax assets, all of which should support earnings growth. These factors provide a clear path for Bradesco to return to high-teens ROE, which we believe is not yet fully reflected in the current valuation.<a href="https://www.hfbestideas.com/?q=BBDC4+BZ&page=1">Access our full research database on Banco Bradesco S.A.</a><div><hr /></div><h3>Burford Capital $BUR FP by Focus Capital Management</h3>Thesis: Burford Capital is a litigation finance company whose core portfolio and optionality appear materially undervalued despite the setback in YPF.Source: https://drive.google.com/file/d/1Cg7j_FjEWJaa7h9FWkGotDd2-ErPiX9w/view?usp=drivesdkAnalysis: Out of all of Burford’s many litigation investments, the YPF cases have always drawn intense market interest, and deservedly so, given their immense size and potential return to Burford. Having initially won an unprecedented $16.1 billion in the Southern District of NY, Burford’s own share of this award amounted to $7 billion+, including accrued interest to date. Naturally, Argentina was avoiding payment in every which way possible, including by appealing the underlying verdict. In recent months, the market has been very nervous that Argentina would win its appeal, a fear that materialized on March 27th when the Second Circuit reversed the lower court’s ruling against Argentina. The market’s reaction was swift and harsh, cutting Burford’s market cap in half. We believe the market has grossly overreacted and that Burford’s stock is enormously undervalued at these levels — a virtual steal. In this Position Paper, we will walk through our thinking on Burford and why we view it as so undervalued. First, we’ll discuss what the YPF appeals ruling actually said and its effects on the YPF litigation. Then, we’ll discuss Burford’s overall valuation and prospects going forward. The bottom line is that although the YPF litigation is not zeroed, it is substantially weakened. Some recovery is still possible, but it will take far longer and has become far less certain than it appeared before the reversal. Does This Change the Thesis? No. This doesn’t change the thesis, because the thesis was never about YPF. We have consistently stated (see our original Position Paper from April 2021, YPF Litigation Value from July 2021, our Portfolio Updates from 2021, 2022, 2024, and 2025, etc.) that the Burford thesis revolves around their core business being greatly undervalued, with YPF as significant and valuable optionality on top, what we often called a cherry on the top or icing on the cake. The YPF option is indeed significantly reduced and possibly eliminated, but the core of Burford remains the same and remains greatly undervalued. In fact, given the market’s reaction, Burford is now even more undervalued than before. Valuing Core Burford One way of looking at valuation is to take their balance-sheet portfolio (ignoring for the moment their business investing third-party funds) which amounts to about $1.75 billion at deployed cost (not counting any fair value adjustments and excluding YPF). Their current portfolio has an average weighted life of 3.3 years, spread across literally hundreds of individual matters. No single case is dispositive to the performance of their portfolio overall (YPF being the exception, not the rule), and they have consistently generated IRRs north of 25% across their overall portfolio for years. Using the average weighted life of 3.3 years and a blended IRR of 25%, we reach a gross portfolio value of $3.65 billion. Subtracting approximately $2.2 billion of debt and adding in $800 million in cash and receivables from settlements yields a net portfolio value of approximately $2.25 billion. The continued IRR at 25% a year means that the portfolio is increasing in value in excess of $900 million a year. Against that, we have to deduct the operating expenses from their legal and administrative staff and financing expenses from their bond issues. All in all, they are spending about $300 million a year, much of that to grow the business even further. Even after accounting for all expenses, their net portfolio is still increasing in value by about $600 million a year, representing growth of about 16.5% on their gross portfolio and nearly 27% on their net worth. Even if we were to assume that future IRRs decline to only 20% — a meaningful haircut from historical performance — the numbers remain excellent. Portfolio value drops to roughly $3.2 billion, net worth to approximately $1.8 billion, and annual value creation (net of expenses) to around $340 million a year. That’s still more than 10.5% growth on their gross portfolio and close to 19% on their net worth. Needless to say, these are excellent business economics. The downside is that these numbers are masked by lumpy and unpredictable returns in any particular quarter or year. But that doesn’t make these numbers less real. And when the market is valuing the entire company at a market cap of $1 billion, it sure seems like a steal. At a valuation of $1 billion, you are receiving a net portfolio worth $1.8–$2.25 billion and growing, after all expenses, by $340–$600 million a year. For just $1 billion! The above calculations account zero for YPF, which may or may not end up returning significant value. They account zero for their third-party fund business, which brings in tens of millions a year and is likely to bring in substantially more as older funds wind down. The undervaluation is astounding. The market is simply hyperfocused on YPF and ignoring the entire rest of the business. The Runoff Thought Experiment Let’s look at it from a different lens. Let’s imagine the worth of Burford if they stopped investing into further cases and simply wound down their present portfolio. Burford shares their own internal estimate of their current portfolio’s ultimate cash realizations, calibrated to their historical track record of hitting their model projections. This is not their optimistic, rosy view of what they may make if everything goes well, but their probabilistic, realistic view of what will likely occur given that some matters will do worse than expected and some will do better, etc. They estimate that the current portfolio will yield $5.2 billion in ultimate realizations plus $350 million in performance allocations from third-party funds. Subtracting their $2.2 billion in debt yields a net runoff value of approximately $3.35 billion, before accounting for operating costs over the wind-down period. (We do not add cash back to this calculation because the above projections assume further deployments to shepherd the present portfolio to conclusion, which happen to just about offset their cash and receivables balances.) We then subtract the cost of managing the portfolio while in runoff. Let’s imagine it to take 5 years at full operating expenses. This is definitely excessive; in reality, a runoff portfolio would not need the $150 million in opex that they spend, most of which is geared to underwrite new cases and further grow the company. And you would presumably be paying off debt as you go, dramatically reducing the finance expenses as well. But for our thought experiment, let’s imagine 5 years at $300 million, for a total of $1.5 billion. That would still leave the runoff value of the present portfolio, net of debt and expenses, using rather draconian assumptions, at a net value of $1.85 billion. This is a “the company is dead” scenario. And in this scenario, estimated super-conservatively, their present book of business is worth almost twice the current market cap, without counting a penny for YPF. But Burford is not dead. On the contrary, Burford is alive and growing. Plenty of Optionality In addition to their core business, Burford has the potential to win very large sums in specific single cases. This is very much not the thesis, but this does remain a real source of possible value that deserves mention. As should be clear from the discussion above, the YPF cases themselves may well end up bringing significant value to the company. But that’s not their only large iron in the fire. Other cases have potential to become outsized home runs as well. There’s more than one, but I wish to zoom in on the Sysco protein cases. We’ve spoken about the Sysco cases before (see our 2023 Portfolio Update and 2024 Portfolio Update). The unusual feature of these cases is that after a protracted and winding litigation between Burford and their client (Sysco), the protein cases have been fully assigned to Burford, so that they get the entirety of any recovery and they control the litigation strategy and settlement. The protein cases are seeking to recover damages owed to Sysco from overcharging by chicken, beef, pork, and turkey cartels that were colluding in violation of antitrust laws. The underlying facts are quite strong, and the defendants have already been found guilty in parallel criminal proceedings. There have been multiple guilty pleas and admissions of guilt from the companies involved, and a number of executives have been indicted. The antitrust violations are not in dispute and the question now is not if, but how much. Given the billions of dollars in underlying purchases by Sysco per year and the multi-year period of the collusion (ranging from 7 to 11 years, depending on the specific protein), calculated damages are highly significant. And by statute, antitrust damages proven at trial are automatically trebled. Earlier in the case, Burford suffered some temporary setbacks, but things appear to be shaping up for them now. Earlier this year, the Seventh Circuit reversed a previous district court finding and ruled that Pilgrim’s Pride had not actually executed a settlement with Sysco for a measly $50 million, one that Burford has long been seeking to void. With that settlement now deemed void, Burford is again in a strong negotiating position with Cargill, Tyson Foods, Pilgrim’s Pride, and the many other defendants, all of which are facing pressure to settle or face a good chance of trebled damages and responsibility to pay for the whole conspiracy. (All co-conspirators in antitrust cases are jointly and severally responsible for the entire conspiracy’s damages and do not by law have recourse to demand restitution from their co-defendants if they are forced to pay more than their “fair share”.) Trials for the pork and turkey cases are scheduled for later this year. The chicken case is getting close to trial and will probably be a late 2027 or early 2028 event. The beef case is moving the slowest, but will get there. The value to Burford can easily reach $1–$2 billion from these cases alone, and is likely to be quite significant even if it doesn’t quite reach those rarefied heights. And the defendants here are all well-capitalized, US corporate defendants. Recovery of any damages awarded at trial is all but certain, without the enforcement uncertainty that we saw with the YPF cases against Argentina.<a href="https://www.hfbestideas.com/?q=BUR+FP&page=1">Access our full research database on Burford Capital</a><div><hr /></div><h3>CoStar Group, Inc. $CSGP US by Baron Partners Fund</h3>Thesis: CoStar is a real estate information platform with recurring revenue, differentiated data assets, and long-term growth opportunities.Source: https://drive.google.com/file/d/1_U7UIRHhzMuTErKyYhvO2FGdVRCLWRO1/view?usp=drivesdkAnalysis: CoStar is the leading provider of information and marketing services to the commercial and residential real estate industries. The stock has been weighed down by significant growth investment in CoStar’s residential product, where sales performance has remained modest and competition is intense. We are encouraged by improving momentum as the company builds out its dedicated residential sales force, enhances its customer targeting, and potentially benefits from changes in Multiple Listing Service practices. We also expect growth in CoStar’s non-residential business to accelerate as sales productivity ramps and the sales team refocuses on core offerings, a trend likely to be amplified by 20% sales force growth in 2025 alone. We believe the value of CoStar’s core non-residential business exceeds the current share price of the stock, suggesting that investors are ascribing little value to the long-term residential opportunity. CoStar Group, Inc. is the leading provider of information and marketing services to the commercial and residential real estate industries. Shares fell due to multiple compression driven by rising AI fears. The market has come to view AI as an existential risk for a growing number of industries—including software, business services, information services, and video games— despite no evidence of any fundamental impact to these sectors. This “shoot first and ask questions later” dynamic has resulted in meaningful share price declines. We continue to own CoStar given its differentiated data assets and significant growth opportunities in providing enhanced real estate information, analytics, and marketplace offerings. CoStar boasts an enviable business model with high levels of recurring revenue and meaningful cash flow generation potential. While near-term cash flow is obscured by elevated investment in Homes.com, we expect spending to moderate and cash flow to improve over the next several years. The company also maintains a substantial cash balance, which we are hopeful will be used to aggressively repurchase shares at current depressed valuation levels.<a href="https://www.hfbestideas.com/?q=CSGP+US&page=1">Access our full research database on CoStar Group, Inc.</a><div><hr /></div><h3>Danaher $DHR US by Eagle Capital Management</h3>Thesis: Danaher is a leading life sciences company with high share, strong management, and improving growth prospects.Source: https://drive.google.com/file/d/1bZbrSrpjogIiVLIcrjLKmQHg8NYuuEoF/view?usp=drivesdkAnalysis: We’ve built a position in Danaher, a leading life sciences company. Danaher sells a broad mix of consumables and tooling that are mission-critical to biological R&D, diagnostic testing, and biopharma drug production. It has high market share, differentiated technology, strong management, and good growth prospects. Over the last several years, Covid-related revenue disappeared, the biotech end-market boomed and then crashed, China slowed, and NIH funding was cut. As a result, this historically stable grower has been anything but stable or growing. It’s now trading at a depressed multiple on depressed earnings. With lower-quality earnings flushed out of the base and other parts running below trend, we expect improving, and possibly even above trend, growth over the coming years. Moreover, one of the most exciting areas of exploration for AI technology is in biopharma research. This has the potential to be a medium- to long-term accelerant for Danaher’s business. We expect EPS growth in the mid-teens.<a href="https://www.hfbestideas.com/?q=DHR+US&page=1">Access our full research database on Danaher</a><div><hr /></div><h3>Dassault Systèmes $DSY FP by Harding Loevner International Equity</h3>Thesis: Dassault Systèmes is a software company with strong margins, steady growth, and AI-enabled product development.Source: https://drive.google.com/file/d/1pkC-EARHS0BMHNFxo3ERCQ0NWWjlMB7d/view?usp=drivesdkAnalysis: Among our software holdings, Dassault Systèmes continues to generate strong margins and steady growth while investing in domain-specific AI agents that capitalize on decades of expertise across aerospace, automotive, health care, and other industries. NICE has also been integrating AI into its products in ways that can lower client costs and improve functionality. OBIC maintains a strong position among mid-sized Japanese firms in enterprise resource planning integration and support and continues to gain share with larger enterprises.<a href="https://www.hfbestideas.com/?q=DSY+FP&page=1">Access our full research database on Dassault Systèmes.</a><div><hr /></div><h3>Ducommun $DCO US by Diamond Hill Small Cap Fund</h3>Thesis: Ducommun is an aerospace and defense manufacturer benefiting from defense spending growth, pricing power and margin expansion.Source: https://drive.google.com/file/d/1P8nIRYL7pq5Utf_u41Lq-60nXGu8QNbD/view?usp=drivesdkAnalysis: Shares of aerospace and defense manufacturer Ducommun rose as its missile franchise, representing roughly 25% of its defense revenue, is directly benefiting from the Pentagon’s spending acceleration. Additionally, the company’s expansion into engineered products creates pricing power and margin expansion that traditional manufacturers cannot replicate, allowing the company to grow end markets while expanding profitability in a rising defense spending environment.<a href="https://www.hfbestideas.com/?q=DCO+US&page=1">Access our full research database on Ducommun</a>

<a href="https://hfbestideas.substack.com/p/50-pitches-found-in-hedge-fund-reports">
Read more
</a>